IGH/CCND1 Translocation, Dual Fusion
- CCND1, 11q13.3, Red
- IGH, 14q32.33, Green
The IGH/CCND1 product consists of probes, labelled in green, covering the Constant, J, D and Variable segments of the IGH gene, and CCND1 probes, labelled in red. The CCND1 probe mix contains a 155kb probe centromeric to CCND1 gene, covering a region between the D11S2663 and the D11S4095 markers, and a second probe (162kb) covering the telomeric end of CCND1 gene and the region up to FGF3 gene.
Although translocations involving IGH and CCND1 (BCL1) were initially reported in B-CLL patients, the rearrangement is now considered to be a hallmark of mantle cell lymphoma (MCL).
Reciprocal translocations involving the IGH and CCND1 (previously known as BCL1) loci, t(11;14)(q13;q32), have been reported in B-CLL patients1. The involvement of the CCND1 (Cyclin D1) gene was initially reported from a cloning study looking at the breakpoints of the translocation. However, it is likely that the initial diagnosis on the samples used for the study should have been mantle cell lymphoma (MCL). The CCND1/IGH probe for detection of t(11;14) has been recommended by the British Committee for Standards in Haematology to enable atypical B-CLL patients to be distinguished from possible MCL patients2.
I am grateful for the excellent products I receive from Cytocell at a reasonable price, but more importantly the superb customer support. The speed in which I receive answers or suggestions makes my life as a director much easier and allows me to focus on patient care. The quality and consistency of Cytocell’s probes means I can trust the results, and my clients get their results in a timely manner. Dr. Theresa C. Brown, Director, Cytogenetics Laboratory, Hayward Genetics Center, Tulane University School of Medicine
1. Brizard et al., Leuk Lymphoma 1997;25(5-6):539-43
2. Parker et al., Best Practice in Lymphoma Diagnosis and Reporting; Specific disease appendix 2010, p5
- Area of Interest*
- CLL, Lymphoma
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.